1. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. (August 2019) Authors: Martín, M.; Loibl, S.; Hyslop, T.; De la Haba-Rodríguez, J.; Aktas, B.; Cirrincione, C.T.; Mehta, K.; Barry, W.T.; Morales, S.; Carey, L.A.; Garcia-Saenz, J.A.; Partridge, A.; Martinez-Jañez, N.; Hahn, O.; Winer, E.; Guerrero-Zotano, A.; Hudis, C.; Casas, M.; Rodriguez-Martin, C.; Furlanetto, J. Journal: European journal of cancer Issue: Volume 117(2019) Page Start: 91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗